Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).

Oncotarget · 2016 · PMC5341855 · PMID 27563810

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendp=0,1so close (0.05 < p ≤ 0.1)

The analysis of the correlation of the MAP17 mRNA levels and IC50 to bortezomib showed a trend (ANOVA, p=0,1) indicating that cells with higher levels of MAP17 are more sensitive to bortezomib than cells without MAP17 (Figure 4A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.